



HPV-Vaccines

Collection Editor:

Dr. Gloria Calagna

“Villa Sofia Cervello” Hospital,
University of Palermo, 90133
Palermo, Italy

Message from the Collection Editor

Dear Colleague,

Human papillomavirus (HPV) is closely related to the pathogenesis of cervical cancer and many other cancers. HPV vaccines are vaccines that prevent infection with certain types of human papillomavirus. However, despite the various prevention strategies and treatments, such as HPV screening, prophylactic HPV vaccines, surgery, radiotherapy, and chemotherapy, the disease burden remains heavy worldwide. Currently, three types of prophylactic vaccines—quadrivalent HPV vaccines, bivalent HPV vaccines, and a new nonavalent HPV vaccine—are commercially available. Although these vaccines protect against 90% of HPV infections, their capacity to eliminate pre-existing infections is limited.

In this Topical Collection, we aim to systematically cover the progress, current status, and future prospects of various vaccines in development for the prevention and treatment of HPV-associated lesions and cancers.

Dr. Gloria Calagna
Collection Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com